P.4.a.009 Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo-controlled, fixed-dose study

Feltner, Douglas E.; Bielski, Robert J.; Liu-Dumaw, Maria

doi:10.1016/s0924-977x(10)70786-0

Cited by 7 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten weeks of open-label treatment with pregabalin (450 mg/day) resulted in a 56-point (62%) reduction in the LSAS total score for patients who continued into the double-blind treatment phase. This is in contrast to the results of a previous short-term trial, in which significant efficacy was only demonstrated for the 600-mg dose, with only inconsistent efficacy demonstrated for the 450-mg dose on secondary analyses (Feltner et al, 2011).…”

Section: Discussioncontrasting

confidence: 99%

See 1 more Smart Citation

Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder

Greist

Liu-Dumaw²,

Schweizer³

et al. 2011

International Clinical Psychopharmacology

View full text Add to dashboard Cite

The objective of this study was to evaluate the efficacy and safety of pregabalin in preventing relapse in generalized social anxiety disorder (SAD). Patients with Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) generalized SAD, who met responder criteria after 10 weeks of open-label treatment with fixed-dose pregabalin (450 mg/day; n=153), were randomly assigned to 26 weeks of double-blind treatment with pregabalin (450 mg/day) or placebo. The primary a-priori outcome of time to relapse was analyzed using the Kaplan-Meier method and the log-rank test. Double-blind treatment with pregabalin was associated with significant delay in time to relapse versus placebo (P=0.035), and with significantly greater maintenance of symptomatic improvement over 26 weeks on the Liebowitz Social Anxiety Scale total (P=0.012) and subscale scores and on the Marks Fear Questionnaire total phobia (P=0.010) and social phobia (P=0.014) subscales. Pregabalin was generally well tolerated. During the double-blind phase, the adverse events that occurred more frequently with pregabalin compared with placebo were dizziness (11.3 vs. 4.1%) and infection (21.3 vs. 16.4%). The results of this study suggest that pregabalin (450 mg/day) is safe, well tolerated, and has significant relapse-prevention efficacy over 26 weeks in patients with SAD who responded to an initial course of the pregabalin treatment.

show abstract

Section: Discussioncontrasting

confidence: 99%

“…Pregabalin is a novel anxiolytic that acts by binding to the a 2 d protein (Bian et al, 2006;Taylor et al, 2007). In the acute treatment of SAD, the efficacy of pregabalin is limited to the 600 mg per day dose, with lower doses not demonstrating a significant effect relative to placebo (Pande et al, 2004;Feltner et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder

Greist

Liu-Dumaw²,

Schweizer³

et al. 2011

International Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…CT remained superior to FLU + standard error (SE) at the end of the booster period and at 12-month follow-up [24]. Davidson Pivotal trial(s) [40][41][42] Pharmaprojects --copyright to Citeline Drug Intelligence (an Informa business). Readers are referred to Pipeline (http://informa-pipeline.…”

Section: Overview Marketmentioning

confidence: 99%

“…Efficacy of pregabalin at a dose of 450 mg/d was studied in the trials [40,41], and at a dose of 600 mg/d was studied in the trials [40,42]. Nevertheless, it was not possible to perform a meta-analysis because in the study of Feltner et al [40].…”

Section: Comparison Of Three Randomized Studies With Pregabalin In Sadmentioning

confidence: 99%

See 1 more Smart Citation

Pregabalin for the treatment of social anxiety disorder

Kawalec

Cierniak

Pilc

et al. 2014

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

The results of the RCTs have demonstrated efficacy and safety with pregabalin at doses of 600 mg or 450 mg/d for treating generalized SAD. Thus, pregabalin may be an effective therapeutic option, especially for patients who cannot tolerate the adverse effects or who demonstrate a lack of efficacy with SSRIs or SNRIs. In addition to being an alternative therapy to SSRIs or SNRIs, it may also have value as an add-on therapy, either to augment pharmacotherapy or in addition to cognitive-behavioral therapy.

show abstract

Anxiety Disorders: From Bench to Bedside and Beyond

Starke

Fineberg

Stein

2018

Advances in Psychiatry

View full text Add to dashboard Cite

The anxiety disorders are common, associated with high comorbidity and cause considerable disability. Despite effective treatment options, they are frequently misdiagnosed, and management is often sub-optimal. With the recent publication of the DSM 5 and the imminent release of the ICD 11, there have been important debates about how best to catagorise and conceptualise these disorders. In addition, their underlying neurobiology is being explored at multiple levels from systems neuroscience to molecular biology and genetics-an endeavor that is delivering key insights with relevance to clinical practice. Furthermore, several international anxiety disorder treatment guidelines have recently been published, and large systematic reviews and meta-analyses have addressed important questions around clinical management. All of this indicates the need for an update on advances in this rapidly developing field, and this chapter therefore provides an overview of the epidemiology and classification, cognitive-affective neuroscience, and clinical management of the anxiety disorders.

show abstract

P.4.a.009 Efficacy of pregabalin in generalised social anxiety disorder: results of a placebo-controlled, fixed-dose study

Cited by 7 publications

References 0 publications

Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder

Efficacy of pregabalin in preventing relapse in patients with generalized social anxiety disorder

Pregabalin for the treatment of social anxiety disorder

Anxiety Disorders: From Bench to Bedside and Beyond

Contact Info

Product

Resources

About